Navigation Links
Thoratec Announces $30 Million Accelerated Share Repurchase
Date:8/6/2014

PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has entered into a $30 million Accelerated Share Repurchase (ASR) agreement.

"This commitment to capital deployment reflects our ongoing conviction in the long term opportunities in our business," said Gary F. Burbach, President and Chief Executive Officer.  "Furthermore, our strong financial position will enable us to evaluate the potential for additional capital deployment in a consistently disciplined manner that allows for meeting our top priorities of internal growth and strategic initiatives," he added.

The ASR will begin in the coming days and complete execution during the third quarter, and is being conducted under the $200 million share repurchase authorization approved by the Board of Directors in December 2013.  Additional repurchase activity may take place on the open market or in privately negotiated transactions from time to time based on market and other conditions, and the program may be modified, suspended, terminated, or extended by the company at any time without prior notice. 

Thoratec is a world leader in therapies to address advanced-stage heart failure.  The company's products include the HeartMate II® LVAS (Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.

Thoratec, the Thoratec logo, and HeartMate II are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

The preceding paragraphs contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "should," "hopes," "could," "will," "may," "estimates," "potential," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products, including development and clinical trial timing, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, the effects of FDA or foreign regulatory authority requirements, our ability to address quality issues adequately and on a timely basis without a resulting recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, and the effects of competition. Forward-looking statements contained in this press release should be considered in light these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Schedules First Quarter Conference Call, Webcast
2. Thoratec Reports First Quarter 2012 Results
3. Thoratec Schedules Second Quarter Conference Call, Webcast
4. Thoratec Reports Second Quarter Results
5. Thoratec Announces Presentations At Upcoming Investor Conferences
6. Thoratec Reports Third Quarter Results
7. Thoratec Presentation At Credit Suisse 2012 Healthcare Conference To Be Webcast
8. Thoratec Presentation At Piper Jaffray 24th Annual Healthcare Conference To Be Webcast
9. Thoratec Presentation At Oppenheimer 23rd Annual Healthcare Conference To Be Webcast
10. Thoratec Schedules Fourth Quarter Conference Call, Webcast
11. Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Conn. , Feb. 11, 2016  AfterPill.com is ... to recommend alcohol abstinence for all women who are ... in the U.S. each year and raises the risks ... --> --> According to the Guttmacher ... 70% of women of child-bearing age, who have sex ...
(Date:2/11/2016)... , 11 de fevereiro de 2016  A ... sua fábrica de soroalbumina bovina (BSA -- ... fábrica fica na Ilha Norte da Nova Zelândia, ... e estabelecido na fábrica da Proliant nos EUA, ... O projeto e instalação dos equipamentos foram feitos ...
(Date:2/11/2016)... INDIANAPOLIS , Feb. 11, 2016 /PRNewswire/ ... people, but for those with type 1 diabetes, the ... students juggle class schedules, assignments and campus activities, they ... 1 diabetes. On top of that, many are living ... Diabetes Scholars Foundation (Foundation) Lilly Diabetes Tomorrow,s Leaders ...
Breaking Medicine Technology:
(Date:2/12/2016)... San Rafael, CA (PRWEB) , ... February 12, 2016 , ... ... camps outside Des Moines, Iowa. Legacy Golf Club, located in Norwalk, serves as the ... Teacher of the Year, Rob Randall. , “We have had successful camps in recent ...
(Date:2/12/2016)... ... February 12, 2016 , ... The aging ... field of long term care. With that, says Patrick Loughney, president of ... administrative roles in long term care environments. His company, which offers prep courses ...
(Date:2/12/2016)... ... February 12, 2016 , ... With the exception of restorative dentistry, to date there ... With the recent approval by the FDA, there is a now a new protocol ... varnish, SDF is very simple and quick to apply. The application is as simple ...
(Date:2/11/2016)... Los Angeles, CA (PRWEB) , ... February 11, 2016 , ... ... Weight Loss System, a product marketed as a weight loss dietary supplement, is being ... Angeles medical group Beverly Hills Physicians, because there is not a single supplement on ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... performing a wide range of cosmetic procedures. Along with performing procedures, the magazine ... and results of many cosmetic procedures. One of the most common procedures he ...
Breaking Medicine News(10 mins):